Introduction
The last two decades witnessed the publication of a large number of clinical outcome trials of blood pressure lowering agents in hypertensive patients or normotensive subjects with a high cardiovascular risk profile. Placebo-controlled trials of antihypertensive drug treatment in middle-aged or older hypertensive patients predominantly with diastolic hypertension 1 proved that a 5-6 mmHg decline in diastolic pressure maintained over 5 years diminished the incidence of stroke by nearly 40% and that of coronary endpoints by 15%. Similarly, in older patients with isolated systolic hypertension, pharmacological intervention during 4 years reduced systolic pressure on average by 10 mmHg and decreased cardiovascular mortality by 18%, all cardiovascular complications by 26%, stroke by 30%, and coronary events by 23%. 2 Until recently, the consensual interpretation of the evidence produced by the outcome trials in hypertensive patients was that blood pressure is a risk factor amenable to intervention, lower levels leading to fewer complications. However, the HOPE trial 40, 41 gave rise to the hypothesis that angiotensin-converting enzyme inhibitors (ACEIs) might reduce cardiovascular complications beyond blood pressure control. Subsequently published trials of angiotensin II receptor blockers (ARBs) in hypertensive patients with renal failure [42] [43] [44] or left ventricular hypertrophy 45, 46 turned this concept into a major argument for drug marketing. The objectives of this editorial are to highlight the contribution of blood pressure lowering in the prevention of cardiovascular complications and to propose from a scientific perspective new research priorities for clinical trials in hypertension.
Older vs newer antihypertensive drugs
We recently reviewed nine outcome trials in 62,605 hypertensive patients, who had been randomized to conventional therapy with diuretics or -blockers or to initial treatment with newer classes of antihypertensive drugs, such as calciumchannel blockers (CCBs), ACEIs, or -blockers. 47 Compared with conventional therapy, CCBs and ACEIs offered similar overall cardiovascular protection, but CCBs provided more reduction in the risk of stroke (−13.5%; 95% CI −1.3 to −24.2%; Pϭ0.03) and less reduction in the risk of myocardial infarction (19.2%; 95% CI 3.5-37.3%; Pϭ0.01). 47 These cause-specific outcome results confirmed the findings of the Blood Pressure Lowering Treatment Trialists' Collaboration. 48 However, the wide confidence intervals demanded a cautious interpretation. 47, 48 A recent update of our meta-analysis ( Fig. 1) (Fig. 1) . † Among the actively controlled trials, 47 we found significant heterogeneity in the outcomes of old and new drugs (Fig. 1) . This was partly due to the higher risk of cardiovascular endpoints (odds ratio 1.25), stroke (1.19), and heart failure (2.04) on treatment with doxazosin compared with chlorthalidone in the ALLHAT trial 33 as well as to the higher risk of stroke (1.25) on captopril than on conventional therapy in the CAPPP study 27 ( Fig. 1) .
Secondary prevention trials in high-risk patients
Several recently published trials 35, 36, [39] [40] [41] 44 tested the hypothesis that agents that inhibit the reninangiotensin system are more effective than placebo in the secondary prevention of the cardiovascularrenal complications of hypertension. These agents reduced the incidence of cardiovascular events 40, 41 and stroke recurrence 39 as well as the risk of overt nephropathy in diabetic patients with normoalbuminuria 41 or microalbuminuria, 44 but they did not reduce the rate of progression of coronary 36 or carotid 35 atherosclerosis. Furthermore, in patients with overt nephropathy due to diabetes 42, 43 or hypertension, 49 ACEIs 49 or ARBs 42, 43 were more effective than conventional therapy 43 or amlodipine 42, 49 in postponing a doubling of the serum creatinine concentration or preventing end-stage renal disease. In keeping with Fleckenstein's animal experiments, 50 two placebo-controlled trials 51, 52 and three trials with diuretics as reference treatment 16, 53, 54 showed that CCBs are able to slow the progression of atherosclerosis. In older hypertensive patients with diabetes mellitus but normal renal function, therapy starting with a longacting dihydropyridine, reduced the incidence of proteinuria by 68% (Pϭ0.008).
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A meta-regression analysis
In middle-aged and older patients, systolic pressure is the prevailing blood pressure component with regard to cardiovascular prognosis. 56, 57 Significant differences in systolic pressure of 2-3 mmHg subsisted between the groups randomized in four trials comparing conventional therapy with the newer classes of antihypertensive drugs. 16, 27, 32, 33 As reported earlier, two of these trials 27, 33 caused significant heterogeneity in the overall outcome results of actively controlled trials. 47 Obviously, the differences in achieved systolic pressure between patients allocated active treatment and placebo were significant in primary as well as secondary prevention trials. The systolic/diastolic differences were 2/0 mmHg in RENAAL, 43 3.3/ 1.0 mmHg in HOPE, 40 5/2 mmHg in PATS, 14 5/2 mmHg in PROGRESS patients on monotherapy with perindopril, 39 12/5 mmHg in PROGRESS patients on combined treatment with perindopril and indapamide 39 and 4.6/3.1 mmHg in PART2 and SCAT taken together, being two smaller secondary prevention trials of ACEIs vs placebo with similar design.
A recently published 47 and subsequently updated 58 meta-regression analysis (Fig. 2) included 149,407 patients randomized in 30 trials. Net treatment effects on systolic pressure were determined by subtracting the mean change in the experimental group (follow-up minus baseline) from the corresponding mean change in the reference group. Experimental groups were those assigned to the therapy to be tested (active vs placebo, new vs old drugs or tight vs less tight blood pressure control). We correlated odds ratios of experimental vs reference treatment with the corresponding differences in systolic pressure. For these calculations, odds ratios were logarithmically transformed. The regression lines were weighted by the inverse of the variance of the individual odds ratios. The differences between the observed odds ratios and those predicted by the meta-regression lines did not reach statistical significance for cardiovascular mortality, collective cardiovascular † Dr H. events, stroke, and myocardial infarction (including sudden death), 47, 58 except for stroke in the NORDIL, 32 and PROGRESS 39 trials. In NORDIL, 32 the risk of stroke was lower on diltiazem (odds ratio 0.81; 95% CI 0.65-1.01) than on conventional drugs despite a 3.1 mmHg higher systolic pressure. In the perindopril-only subgroup of the PROGRESS trial, 39 systolic pressure was reduced by 5 mmHg, but monotherapy with the ACE inhibitor did not affect the risk of all cardiovascular events (odds ratio 0.96; 0.80-1.15) or stroke recurrence (odds ratio 0.95; 95% CI 0.77-1.19). Thus, for the endpoints reviewed in our meta-regression analysis (Fig. 2) , the benefit of antihypertensive treatment could be explained by blood pressure lowering.
Benefit beyond blood pressure lowering?
LIFE was a double-blind parallel-group trial involving 9193 patients randomized to first-line treatment with losartan or atenolol to test the hypothesis whether selective blockade of type-1 angiotensin II receptors might reduce the incidence of cardiovascular morbidity and death beyond blood pressure control. 12 In all patients combined, 46 blood pressure fell by 30.2/ 16.6 mmHg in the losartan group and by 29.1/ 16.8 mmHg in patients allocated atenolol. In 1195 diabetic patients, 46 these decreases amounted to 31/17 and 28/17 mmHg, respectively. The primary endpoint consisted of non-fatal myocardial infarction, non-fatal stroke, and mortality due to myocardial infarction, stroke, sudden death, heart failure, or other cardiovascular causes. In the losartan compared with the atenolol group, relative risk decreased by 13% (95% CI 23-2%; Pϭ0.021) in all patients 46 and by 24% (95% CI 23-2%; Pϭ0.031) in the diabetic subgroup. 45 From the published reports, 45, 46 we calculated the outcome results in the 7998 non-diabetic patients and compared noncardiovascular mortality according to randomization in diabetic as well as in non-diabetic patients (Fig. 3) . The researchers of the LIFE study 45, 46 reported that adjustment for on-treatment blood pressure had little effect on endpoints. Their conclusion was that first-line treatment with losartan, compared with atenolol, improved outcome over Fig. 2 Published odds ratios for cardiovascular events were regressed on baseline-adjusted net differences between randomized groups across 30 trials. The regression line was plotted with 95% CI, was adjusted for the mean systolic pressure at entry, and was weighted for the inverse of the variance of individual odds ratios. Filled symbols denote trials that compared new with old drugs. Acronyms of trials are given in Appendix A. The data have been reproduced with permission. 47 and beyond blood pressure control. 45, 46 They did not consider the alternative hypothesis that atenolol might have fallen short of the expectation based on the decline in blood pressure. 59 The LIFE investigators measured achieved blood pressure at the end of follow-up (mean 4.8 years) or just before an event. 45, 46 This definition did not account for the differences in systolic pressure (higher on atenolol), diastolic pressure (lower on atenolol), or pulse pressure (higher on atenolol), which occurred during the first years of follow-up. In the -blocker compared with the losartan group, more patients withdrew from double-blind medication (27.1 vs 22.6%; P<0.001), whereas fewer proceeded to combination therapy (61.7 vs 65.9%; P<0.001). The LIFE consortium did not publish the parameters of fully adjusted Cox models, including an appropriate component of the on-treatment blood pressure (systolic pressure or pulse pressure) as well as the interaction between randomization group and achieved blood pressure. This interaction term tests whether for the same on-treatment blood pressure, outcome significantly different according to randomization. The decrease of non-cardiovascular mortality by 42% (95% CI 5-65%; Pϭ0.03) in the diabetic LIFE patients (Fig. 3) , which we noticed in our calculations from the published outcome data, 45, 46 remains unaccounted for. There is consensus that -blockade reduces the incidence of sudden death, especially among patients with left ventricular dysfunction. 60 Nonetheless, sudden death was not included in the definition of myocardial infarction nor analysed as a separate endpoint. Stroke is the hypertensive complication, which is most amenable to prevention even by a few millimetres mercury reduction in blood pressure. 1, 47 The beneficial outcome in the losartan group 46 was mainly driven by a reduction of the stroke rate (Fig. 3) . In our view (Table 1) , the LIFE trial results as well as those of two other trials in patients with left ventricular dysfunction 61, 62 did not deviate from what one might expect based on the differences in achieved systolic pressure, which averaged 1 mmHg in all LIFE patients, 46 3 mmHg in the diabetic subgroup of the LIFE trial, 45 and 6 mmHg in two other trials. 61, 62 We believe that by taking the blood pressure at the end of follow-up the systolic blood pressure gradient between the groups randomized in the LIFE trial was underestimated by 2-3 mmHg. Accounting for an unbiased on-treatment systolic pressure might even move the LIFE data points to the right closer to the regression line than suggested by our plot (Fig. 4) .
Economic implications of trial results
Statistics over 12 months to March 2000 showed that hypertension was the leading diagnosis for drug prescriptions to patients older than 50 years both in Europe and in North America. 63 In both Fig. 3 Outcome results in diabetic and non-diabetic patients randomized in the LIFE trial. Results for non-cardiovascular mortality and those for non-diabetic patients were calculated from unadjusted outcome data. 45, 46 markets, around one in four prescriptions for hypertension was for ACEIs (plain or in combination), while a further one in five was for calcium-channel blockers (plain). Diuretics were the third most common treatment and together with -blockers accounted for almost 30% of all prescriptions written for hypertension. ARBs are the fastest-growing class of antihypertensive agents with a 5-10% market share. Sales of cardiovascular drugs at retail pharmacies in the main markets of Europe, the Americas, and Japan totalled approximately V 52,000 million. 64 In an era of strong reliance on evidence-based treatment guidelines, 65,66 clinical outcome trials are increasingly becoming a marketing tool for antihypertensive drugs. The silent infiltration of commercial incentives into the scientific objectives of clinical trials increases the probability of selective presentation or a one-sided interpretation of the results. The saying that one sees only what one looks for is bearing upon the matter. Patient characteristics and reference drugs may be chosen to maximize the probability of success. Although selection substantially narrows the external validity of trials, results may nevertheless be presented as being applicable to unselected patients with or without hypertension. Furthermore, sponsors may decide to close clinical trials prematurely, if business interests will not be met or change over time. 45, 46 for captopril vs placebo in SAVE, 61 and for enalapril vs placebo in SOLVD. 62 b Odds ratio (95% CI) predicted by meta-regression (see Fig. 2 ). 47, 58 c Significance of the difference between observed and predicted odds ratios. d Baseline-adjusted systolic differences favoured losartan in the LIFE trial 45, 46 and active treatment in SAVE 61 and SOLVD.
Blinded validation of disease outcomes in open
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Fig. 4 Odds ratios for cardiovascular events in all LIFE patients (LIFE/ALL), 46 in diabetic LIFE patients (LIFE/DM), 45 and in two trials of ACEIs vs placebo in patients with left ventricular dysfunction. 61, 62 The published odds ratio were plotted as a function of the observed differences in systolic pressure between randomized groups and were superimposed on the meta-regression model given in Fig. 3 . trials 67 saves costs. However, this design does not rule out the possibility that prior knowledge of treatment allocation results in selective overreporting or under-reporting of events. Rates of adverse effects, such as for instance ankle oedema on CCBs or cough on ACEIs, are on average twice as high in open trials as in double-blind studies.
Perspective on future trials in hypertension
Benefit beyond blood pressure control has been a leading theme in comparative trials in hypertensive patients, 45, 46 in placebo-controlled studies in highrisk normotensive and hypertensive patients, [39] [40] [41] and in recently published trials in patients with diabetic nephropathy. [42] [43] [44] Notwithstanding, the publicity on which drug is the better choice to initiate antihypertensive treatment, this is largely an obsolete question. The reductionist idea that interference with a single pathophysiological mechanism 40, 41, 45, 46 provides a leading edge in the treatment of hypertension is an oversimplification that ignores the heterogeneous nature of this disorder. The overwhelming majority of hypertensive patients have to proceed to combination therapy to achieve blood pressure control. 22 A host of other research themes with far larger clinical relevance must be addressed. A few examples are given below.
Regulators continue to approve drugs for antihypertensive treatment based on their potential to lower blood pressure, an intermediate endpoint. In spite of the overwhelming evidence highlighting the risk of systolic hypertension in the elderly 2 and the risk possibly associated with a forced reduction of a normal diastolic pressure, 68 regulators still insist that both systolic and diastolic blood pressures must be lowered for a new drug to be approved. The hypothesis that in older patients selective lowering of systolic pressure, for instance by long-acting nitrates, 69 might improve prognosis more than the indiscriminate reduction of both systolic and diastolic pressures, remains to be tested. A further and more compelling issue is whether blood pressure lowering can prevent vascular and neurodegenerative dementia. In placebocontrolled trials, treatment based on thiazides, 8, 70 -blockers, 8, 70 the ACEI perindopril given in monotherapy 39 , ‡ or the ARB candesartan 71, § failed to protect against cognitive impairment and dementia. 2, 3 In contrast, therapy initiated with nitrendipine reduced the incidence of dementia by half. 72, 73 Dihydropyridine CCBs cross the bloodbrain barrier 74, 75 and reduce the turnover of monoamine neurotransmitters, 74 of which many are deficient in degenerative dementias. 76 In view of the pandemic of mainly neurodegenerative dementia, 77 the question whether dihydropyridines specifically protect against cognitive impairment 72, 73 must be addressed. Placebo-controlled trials with double-blind design should be mounted to establish the benefit to risk ratio and cost effectiveness of treating mild isolated systolic hypertension in patients without cardiovascular complications 78 and to determine the optimal level to which systolic pressure and pulse pressure 79 must be lowered. In contrast to recent suggestions, 80 there is no evidence that a high-normal blood pressure should be lowered in subjects with average cardiovascular risk. The question to what extent race, 81, 82 gender, 83 and genetic predisposition [84] [85] [86] should be accounted for in prescriptions for individual patients increasingly merits attention. Indeed, the number of hypertensive patients seeking treatment will continuously grow, not only because people live longer and hypertension is age-related, but also because blood pressure thresholds for diagnosis and effective control of the condition may be expected to decline further in the years to come as they did in the past. 78 
Conclusions
In trials in hypertensive and high-risk patients, lower systolic blood pressure was associated with better outcome. Although we did not investigate to what extent blood pressure should be lowered, our findings indicate that blood pressure control is important. On balance, all antihypertensive drugs share similar long-term efficacy and safety. Accepting this point of view, will free resources to address new issues with far greater clinical relevance than the question which drug is better. ).
Appendix A-Acronyms of trials
